Observations placeholder

Olmesartan medoxomil is an angiotensin II receptor antagonist which has been used for the treatment of high blood pressure.  It  is sold under the trade name Benicar Olmecip(Cipla)and Olsar. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form, olmesartan (RNH-6270).

The full prescribing information for Benicar notes as with all drugs that act directly on the renin-angiotensin system, olmesartan is contraindicated in pregnancy and can cause injury and even death to the developing fetus. In studies of angiotensin II receptor antagonists such as olmesartan, patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected. Rarely, olmesartan can cause severe gastrointestinal issues. The symptoms, which include nausea, vomiting, diarrhea, weight loss, and electrolyte abnormalities, are common among those who have celiac disease.

On Jan, 1, 2016: 5,494 people reported to have side effects when taking Olmesartan medoxomil. Among them, 124 people (2.26%) have Death.

Time on Olmesartan medoxomil when people have Death  :

Gender of people who have Death when taking Olmesartan medoxomil  :

Age of people who have Death when taking Olmesartan medoxomil  :

Top conditions involved for these people  :

1. Hypertension (37 people, 29.84%)